Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00363090
Status:
UNKNOWN
Last Update Posted:
2013-09-20
First Post:
2006-08-10
Brief Title:
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II Stage III or Stage IV T-Cell Non-Hodgkins Lymphoma
Sponsor:
Toronto Sunnybrook Regional Cancer Centre
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
CDR0000491451
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Toronto Sunnybrook Regional Cancer Centre
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None